SFX by Ex Libris Inc.

Title:	COX-2-derived prostacyclin confers atheroprotection on female mice
Source:	Science [0036-8075] Egan, K M yr:2004

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Couzin, J. "Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap." Science 306.5700 (2004): 1277-1277.
description	2.	Egan, Karine M M. "Cyclooxygenases, thromboxane, and atherosclerosis - Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism." Circulation 111.3 (2005): 334-342.
description	3.	Burleigh, Michael E E. "Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice." Circulation 105.15: 1816-1823.
description	4.	Satoh, K. "Expression of vascular endothelial growth factor in human umbilical vein endothelial cells stimulated with interleukin-1alpha--an autocrine regulation of angiogenesis and inflammatory reactions." Thrombosis and haemostasis 83.6: 949-955.
description	5.	Mukherjee, D. "Risk of cardiovascular events associated with selective COX-2 inhibitors." JAMA 286.8 (2001): 954-9.
description	6.	Juni, P. "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis." The lancet 364.9450 (2004): 2021-9.
description	7.	Strand, V. "Are COX-2 inhibitors preferable to non-selective non-steroidal anti- inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?" Lancet, The 370.9605 (2008): 2138-2151.
description	8.	Couzin, J. "Estrogen's Ties to COX-2 May Explain Heart Disease Gender Gap." Science 306.5700 (2004): 1277-1277.
description	9.	Paruchuri, S. "Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor." The Journal of experimental medicine 206.11 (2009): 2543-2555.
description	10.	Grunau, Gilat L L. "Ethnic and gender differences in patient education about heart disease risk and prevention." Patient Education and Counseling 76.2 (2009): 181-188.
description	11.	Reisin, L. "[Investigating chest pain--is there a gender bias?]." Harefuah 135.12 (1998): 584-8.
description	12.	Corry, D B B. "Selective aspects of the insulin resistance syndrome." Current opinion in nephrology and hypertension 10.4 (2001): 507-14.
description	13.	London, B. "Taking the gender gap to heart." Circulation research 89.5 (2001): 378-9.
description	14.	Chun lin, L. "Relationship between coronary atherosclerosis plaque characteristics and high sensitivity C-reactive proteins, interleukin-6." Chinese medical journal 124.16 (2011): 2452-2456.
description	15.	Forbes, Josephine M M. "Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis." Diabetes 53.7 (2004): 1813-1823.
description	16.	Viles Gonzalez, Juan F F. "Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition - a magnetic resonance imaging study." European Heart Journal 26.15 (2005): 1557-1561.
description	17.	Howard, A. "Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk." Journal of the American College of Cardiology 43.4 (2004): 519-25.
description	18.	Hulley, S. "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group." JAMA 280.7: 605-613.
description	19.	Pelletier, Jean-Pierre P. "Glucosamine and chondroitin sulfate for knee osteoarthritis." The New England journal of medicine 354.20 (2006): 2184-5.
description	20.	Kim, Peter S S. "Discontinuation of Vioxx." The lancet 365.9453 (2005): 23-7.